Launch Date
10/30/2020 at 8:00 am EST
Credit Amount
0.00 Expired
Credit Expires
01/01/2024
The management of ulcerative colitis (UC) is evolving. In the last 2 years, the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) released updated, evidence-based treatment guidelines with recommendations for disease stratification, prognosis, treatment options, and disease monitoring. Additionally, new efficacy, safety, and comparative effectiveness data from advanced treatment options are now available, and the list is expected to grow with the approval of additional therapies in the future.
In this CME Outfitters webcast, expert faculty will compare the new AGA and ACG guideline recommendations and discuss recent clinical trial and real-world data in order to provide learners with recommendations on selecting the appropriate therapy for individual patients. In addition, faculty will discuss proven strategies to empower, educate, and engage patients in their UC care.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
List the types of medical professionals who will benefit from this course.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Biomica; Boehringer Ingelheim; Bristol-Myers Squibb Company; Celgene Corporation/ Syneos Health; Check-Cap; Dizal Pharmaceutical; Eli Lilly and Company; GalenPharma/Atlantica; Genentech, Inc./Roche; Gilead Sciences, Inc.; GlaxoSmithKline; Ichnos Sciences SA; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and Techlab, Inc. He is a stock shareholder (directly purchased) in AbGenomics and Biomica. He receives other financial or material support as Co-Founder and CFO of Cornerstones Health, Inc.; and Co-Founder of GoDuRn, LLC. (non-profit).
Dr. Anyane-Yeboa reports she serves on the advisory committee for Pfizer Inc. She is a consultant for SidekickHealth.
Dr. Long reports that she receives grants and research support from Pfizer Inc. and Takeda Pharmaceuticals U.S.A., Inc. She is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and UCB, Inc.
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-127-H01-P